Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Infectious disease

How SARS-CoV-2 stops cells producing protein

Cryo-EM shows how the new coronavirus stops the ribosome producing immune system proteins

by Laura Howes
July 25, 2020 | A version of this story appeared in Volume 98, Issue 29

 

The cryoEM structure of the ribosome with Nsp1 bound, blocking mRAN entry.
Credit: Science
This cryo-EM image shows the structure of Nsp1 bound to a ribosome (Nsp1 = pink; ribosomal RNA and proteins = yellow).

The novel coronavirus SARS-CoV-2, cause of the COVID-19 pandemic, has infected millions worldwide, but scientists are still unpacking how infection by SARS-CoV-2 works. Researchers led by Roland Beckmann of Ludwig Maximilian University Munich and Konstantin M. J. Sparrer of Ulm University have now determined how the coronavirus inhibits the synthesis of proteins in infected cells, effectively disarming the body’s innate immune system (Science 2020, DOI: 10.1126/science.abc8665). The team used cryo-EM to image the viral protein Nsp1 in a complex with the human ribosome, the cell’s protein-making factory. The work shows that after Nsp1 binds to the ribosome, one end of the protein inserts into the mRNA entry channel of the ribosome and blocks it, stopping production of immune system proteins. Earlier work had shown that Nsp1 from the virus that causes SARS suppresses protein production, but the mechanism wasn’t clear. Blocking Nsp1 binding without blocking the function of the ribosome could be a good drug target, the researchers say.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.